Core Viewpoint - Gauzy Ltd. is facing legal action due to significant financial distress, including insolvency proceedings for its French subsidiaries, which has led to a drastic decline in its stock price and potential default on debt obligations [2][3][4]. Group 1: Company Financial Situation - On November 14, 2025, Gauzy announced the initiation of insolvency proceedings for three of its subsidiaries in France, which are aimed at preserving business operations and repaying creditors [2]. - The commencement of these proceedings has triggered a default under the company's existing senior secured debt facilities, which could lead to further financial complications if not addressed [2]. - Following the announcement, Gauzy's share price plummeted by $2.00, or 49.8%, closing at $2.02 per share on November 17, 2025, amid unusually high trading volume [3]. Group 2: Legal Action Details - A class action lawsuit has been filed against Gauzy, alleging that the company made materially false and misleading statements regarding its financial health and failed to disclose critical information about its subsidiaries' inability to meet debt obligations [4]. - The lawsuit claims that the defendants did not inform investors about the likelihood of insolvency proceedings and the potential default on senior secured debt, which misled investors regarding the company's true financial condition [4]. - Investors who purchased Gauzy securities during the specified class period (March 11, 2025, to November 13, 2025) have until February 6, 2026, to file a lead plaintiff motion in the class action [5].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Group 1: Class Action Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchases made between February 27, 2023, and November 4, 2025, with a deadline for lead plaintiff applications set for January 16, 2026 [1][8]. - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant for $170 million was marred by significant underinvestment and operational deficiencies [2][3]. Group 2: Financial Implications - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, alongside a 50% decline in earnings per share compared to the previous year, leading to a stock price drop of over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, resulting in a nearly 10% drop in stock price [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an over 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, which included a negative sales growth guidance of -2.5% to -3% and a significant cut in expected earnings per share, leading to a stock price drop of over 25% [7].

Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to significant stock price decline following the company's revision of its 2025 revenue and adjusted EBITDA guidance, attributed to challenges in its Rex MD business [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA, citing temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025, resulting in substantial losses for investors [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and prospects during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - The lawsuit claims that the positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period have until October 27, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Hayward Holdings, Inc. regarding misleading sales practices and inventory levels [1][2] Group 1: Legal Investigation - The firm is looking into allegations that Hayward misled investors about its sales practices and inventory levels [1][2] - A U.S. District Court ruling allows a securities fraud lawsuit against Hayward and its executives to proceed [1] - The lawsuit claims that Hayward engaged in "channel stuffing" between October 2021 and July 2022, artificially inflating sales figures [1] Group 2: Impact on Company Performance - The alleged practices led to an undisclosed inventory glut, negatively affecting future sales [1] - Following the revelation of these practices in July 2022, Hayward's stock price fell by 18% [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to consider their legal options [2][4][5]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company whose stock is traded on NASDAQ under the ticker symbol ALT [2]. - The company recently announced topline results from the IMPACT Phase 2b MASH trial, which did not meet statistical significance for its primary endpoint [4]. Group 2: Legal Actions and Investor Impact - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [2][6]. - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in one day [5]. - The firm encourages any individuals with information regarding Altimmune's conduct to come forward, including whistleblowers and former employees [7].

Core Viewpoint - The Lockheed Martin Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and lack of effective internal controls during the specified class period [1][3]. Group 1: Allegations and Financial Impact - The lawsuit alleges that Lockheed Martin made false statements regarding its internal controls and ability to meet contract commitments, which led to significant financial losses [3]. - On October 22, 2024, Lockheed Martin announced an $80 million loss on a classified program, causing a stock price drop of over 6% [4]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion related to classified programs, resulting in a stock price decline of more than 9% [5]. - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses, including $950 million from its Aeronautics Classified program, leading to a nearly 11% drop in stock price [6]. Group 2: Class Action Process - Investors who purchased Lockheed Martin securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [7]. - The lead plaintiff can select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [7]. Group 3: About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - RxSight, Inc. is facing a class action lawsuit due to significant declines in sales and revenue, leading to a substantial drop in stock price following the release of disappointing financial results for Q2 2025 [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [2]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [2]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [2]. Lawsuit Details - The class action lawsuit alleges that during the Class Period, RxSight's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include: (1) the company faced "adoption challenges" leading to declines in sales and utilization; (2) overstated demand for RxSight's products; (3) unlikelihood of meeting previously issued financial guidance for fiscal year 2025; (4) positive statements about the company's business were materially misleading [3]. Legal Actions - Investors who purchased or acquired RxSight securities during the Class Period can file a lead plaintiff motion by September 22, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth and business strategies [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal rights [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [2]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025 [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and growth [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].